PT-141 (bremelanotide)
An approved drug — for women. Sold to men by clinics that do not always mention that
Our overall score
Written by J. Porter, MPH
Medically reviewed by R. Okafor, PharmD
Last reviewed
The short version
Bremelanotide is a melanocortin receptor agonist that acts on arousal pathways in the brain rather than on blood flow. It is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. It is not approved for men or for erectile dysfunction, and the versions peptide clinics sell — frequently compounded nasal sprays — are a further step from anything reviewed.
Our verdict: The mechanism is genuinely different from everything else on this site, which makes it interesting for low desire rather than mechanical failure. But it is unapproved in men, the male evidence is early, and most of what is sold is compounded rather than the approved product. Treat wellness-clinic peptide offers with the scepticism you would apply to any unapproved injectable.
Best for: Very few people, and only with a clinician who is explicit that this is off-label and why they are recommending it.
What works
- A genuinely different mechanism — it targets desire rather than blood flow
- May help where the problem is low arousal rather than mechanical failure
- The molecule has a real FDA approval behind it, unlike most things sold by peptide clinics
- Early studies in men, including diabetic ED, showed some improvement
- Does not carry the PDE5 nitrate contraindication
What to watch
- Not FDA-approved for men or for erectile dysfunction
- Most clinic-supplied versions are compounded, so not FDA-reviewed at all
- Nausea is a common and frequently dose-limiting effect
- Can raise blood pressure, which matters in a population prone to cardiovascular disease
- Expensive, cash-pay, and typically bundled into a broader peptide programme
- Not part of any ED treatment guideline
At a glance
- How it works
- A melanocortin receptor agonist acting on pathways in the central nervous system involved in sexual arousal. Unlike a PDE5 inhibitor it does not act on penile blood flow, which is why it is framed as a desire drug rather than an erection drug.
- Time to effect
- Roughly within an hour of dosing, per the approved product's labelling
- Safety limit
- Nausea is the most common effect, and it can raise blood pressure — a concern in the population most likely to have ED
- How you get it
- The approved product (Vyleesi) is prescription-only and indicated for women. Use in men is off-label, and clinics frequently supply compounded versions instead
- Regulatory status
- FDA-approved as Vyleesi for HSDD in premenopausal women. Not approved for men, not approved for erectile dysfunction, and compounded nasal sprays are not FDA-reviewed at all
- Typical cost
- Varies widely; wellness-clinic peptide programmes are typically expensive and cash-pay
- Ongoing cost
- Ongoing, on a per-dose basis
- Clinical standing
- Not part of standard ED management. It is not recommended in ED guidance, which is built around PDE5 inhibitors, devices, injections, and surgery
What it is, and what it is approved for
Bremelanotide is a melanocortin receptor agonist. Rather than acting on the blood vessels of the penis, it acts on pathways in the brain involved in sexual arousal — which makes it the only thing on this site aimed at desire rather than mechanics.
That is the same manoeuvre we describe on the shockwave therapy page — an approval for one purpose being presented as validation for another. Ask the specific question: *approved for what, and in whom?*
Off-label is legal, and not automatically wrong
Prescribing a drug outside its approved indication is legal, common, and often good medicine. Several treatments we rate well involve it. So the objection here is not off-label prescribing as such.
It is that off-label use is supposed to rest on clinical judgement about an individual patient. That is a different thing from a wellness clinic building a cash-pay product line around an indication the drug was never assessed for — the same distinction we draw on shockwave.
What the male evidence shows
There is some. Early studies in men with erectile dysfunction reported improvements in erectile function scores, including in men with diabetes-related ED, and later observational work has been broadly positive.
What does not exist is the body of large randomised evidence that sits behind PDE5 inhibitors, or an approval in men. Bremelanotide was investigated for male ED and the approval that eventually arrived was for a different indication in women — which is context worth having.
The compounded nasal spray problem
This is where it gets further from anything reviewed. The approved product is an injection. Many peptide and wellness clinics supply compounded nasal sprays instead.
Side effects worth knowing
- Nausea is the most common effect and is frequently what limits the dose. In the approved product's trials it was prominent.
- Raised blood pressure with a corresponding drop in heart rate — which matters, because ED is disproportionately common in people with cardiovascular disease.
- Flushing and headache are commonly reported.
- Darkening of the skin or gums has been reported with melanocortin agonists, particularly with repeated dosing.
When it might genuinely be worth discussing
The honest case for it is narrow but real. If your problem is that desire has gone rather than that the mechanics have failed, nothing else on this site addresses that directly — PDE5 inhibitors do not create arousal, and testosterone only helps if you are genuinely hypogonadal.
So it is a reasonable conversation to have with a clinician who has first ruled out the ordinary causes of low desire: low testosterone, depression, medication side effects (SSRIs especially), relationship factors, and sleep. If a clinic reaches for a peptide before checking those, that tells you what kind of clinic it is.
Questions to ask
- 1Is this the FDA-approved product, or a compounded version? They are not the same thing.
- 2What indication is it approved for? The honest answer is HSDD in premenopausal women.
- 3Have we ruled out the common causes of low desire first?
- 4What is my blood pressure, and does that make this a bad idea?
- 5What does this cost per dose, and is it bundled into a wider programme I do not need?
- 6Does anyone here have a financial interest in the peptide programme specifically?
Common questions
Is PT-141 FDA-approved for men?
No. Bremelanotide is approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. It is not approved for men, and not approved for erectile dysfunction in anyone. Use in men is off-label, which is legal but means the drug has not been assessed for that use.
How is it different from Viagra?
Completely different mechanism. PDE5 inhibitors act on blood flow in the penis; bremelanotide acts on arousal pathways in the brain. That makes it potentially relevant when desire is the problem rather than the mechanics — and largely irrelevant when the mechanics are the problem.
Are the nasal sprays clinics sell the same thing?
No. The approved product is an injection. Compounded nasal sprays are a different route in a formulation no regulator has reviewed, for an unapproved indication. Compounded products are not assessed by the FDA for safety, effectiveness, or manufacturing quality.
What are the side effects?
Nausea is the most common and often dose-limiting. It can also raise blood pressure while lowering heart rate, which is worth taking seriously in a group prone to cardiovascular disease. Flushing and headache are common, and skin or gum darkening has been reported with repeated use.
Is it the same as Melanotan II?
No, though they are related melanocortin peptides. Melanotan II has no approval anywhere and is sold illicitly online with no quality control and a worse safety record. Buying peptides from a website rather than receiving a prescription puts you in that category.
Sources
- 1.Erectile Dysfunction: AUA Guideline — American Urological Association
- 2.Vyleesi (bremelanotide) prescribing information — U.S. Food and Drug Administration
- 3.Compounding and the FDA: questions and answers — U.S. Food and Drug Administration